Harbour Biomed US, Inc.

Clinical trials sponsored by Harbour Biomed US, Inc., explained in plain language.

Now part of HBM Holdings Limited 2142 HKEX

Biopharma developing antibody-based therapies for cancer and autoimmune diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New cancer drug HBM1020 tested in tiny early trial

Disease control Completed

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

Phase 1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:28 UTC

Harbour Biomed US, Inc.

New cancer drug HBM1020 tested in tiny early trial